Cubist Systematic Strategies, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $6,048 - $32,175	-12,096 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $81,997 - $209,159	-43,849 Reduced 78.38%	12,096 $28,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $195,807 - $471,056	55,945 New	55,945 $266,000
Q3 2021 Nov 15, 2021	SELL	$6.03 - $7.95 $70,683 - $93,189	-11,722 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $38,634 - $51,226	-6,113 Reduced 34.28%	11,722 $82,000
Q1 2021 May 17, 2021	BUY	$6.76 - $8.57 $58,318 - $73,933	8,627 Added 93.69%	17,835 $141,000
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $2,232 - $3,125	318 Added 3.58%	9,208 $72,000
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $11,438 - $16,392	-1,757 Reduced 16.5%	8,890 $63,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $42,694 - $117,542	10,647 New	10,647 $98,000
Q3 2018 Nov 14, 2018	SELL	$8.24 - $11.0 $101,731 - $135,806	-12,346 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $97,163 - $134,447	12,346 New	12,346 $131,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.